Enveric Biosciences, Inc. (ENVB)
1.44
0.00 (0.00%)
USD |
NASDAQ |
Sep 03, 16:00
1.405
-0.04
(-2.43%)
After-Hours: 20:00
Enveric Biosciences Research and Development Expense (TTM) : 2.476M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.476M |
| March 31, 2026 | 2.381M |
| December 31, 2025 | 2.781M |
| September 30, 2025 | 3.514M |
| June 30, 2025 | 3.874M |
| March 31, 2025 | 3.130M |
| December 31, 2024 | 2.841M |
| September 30, 2024 | 3.105M |
| June 30, 2024 | 3.694M |
| March 31, 2024 | 5.692M |
| December 31, 2023 | 7.224M |
| September 30, 2023 | 7.748M |
| June 30, 2023 | 8.452M |
| March 31, 2023 | 8.059M |
| December 31, 2022 | 8.028M |
| September 30, 2022 | 8.627M |
| June 30, 2022 | 7.791M |
| March 31, 2022 | 6.551M |
| December 31, 2021 | 4.750M |
| September 30, 2021 | 2.320M |
| June 30, 2021 | 1.152M |
| March 31, 2021 | 0.2722M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 |
| Date | Value |
|---|---|
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| LENZ Therapeutics, Inc. | 3.791M |
| Impact BioMedical, Inc. | 0.284M |
| ANI Pharmaceuticals, Inc. | 49.91M |
| Corcept Therapeutics, Inc. | 253.86M |
| Veru, Inc. | 11.76M |